July 4th 2025
Significant short-term impact of MDA with dihydroartemisinin–piperaquine plus primaquine in a moderate-to-low transmission setting, highlighting the need for full seasonal coverage and community engagement to sustain gains.
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
A Shield of Protection: Unmet Needs in COVID-19 Prevention and Control
October 7, 2025
Register Now!
Tackling Inequities in IBD: Inclusive Solutions for Elevated Patient Care
View More
Addressing Racial Disparities in Multiple Myeloma: Forging a Path Towards Health Equity in Clinical Trials and Everyday Practice
View More
New Report Calls For Funding Treatments, Greater Emphasis on Chronic Lyme Disease
May 14th 2025A small percentage of people who contract the tick-borne illness have lingering symptoms and health issues after the acute infection has been treated, but there are no FDA-approved therapies to deal with prolonged symptoms. A new report looks to address this issue.
Read More
FDA and CDC Recommend Pause on Chikungunya Vaccine IXCHIQ for Adults 65 and Older
May 12th 2025Regulatory action follows reports of serious adverse events during use in elderly individuals; vaccine remains authorized for younger age groups in the US and Europe with over 40,000 doses administered globally.
Read More
Decoding Malaria Parasites to Aid in Potential Treatments and Vaccines
April 25th 2025The Johns Hopkins Malaria Research Institute’s work in this area is looking to find ways to identify, for the first time, every single gene in the genome of malaria parasites, which could lead to the development of new treatments or vaccines.
Watch
CDC ACIP Meeting Examines Next Steps for Meningococcal, RSV, and Chikungunya Vaccination
April 16th 2025ACIP provides recommendations on meningococcal vaccines, RSV vaccination for at-risk adults, and chikungunya vaccines for travelers and laboratory workers, while also addressing safety concerns and potential expansions of use for each.
Read More